ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 823 participants.

Also called NCT01848639

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 823 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01848639
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, France, Monaco (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01848639. Randomized; triple masking; primary purpose treatment. Start 2013-06 (actual); primary completion 2022-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial
Acronym
ALCHEMIST
Condition
End Stage Renal Failure on Dialysis
Intervention (Drug)
Spironolactone
Intervention (Drug)
Placebo
Lead sponsor
University Hospital, Brest (class: other)
Collaborator
Central Hospital, Nancy, France (class: other)
Collaborator
Institut National de la Santé Et de la Recherche Médicale, France (class: other government)

Record details

Record id
cardio:ct-nct01848639
Content hash
8416b81a57bba208b9cd7451ee7128f6a2d5de928b42ae8ac4e944016bb22449